Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGC Flora Growth	$23.63 +0.6%	$24.37	$15.15 ▼ $82.29	$14.04M	1.97	16,032 shs	24,255 shs
IMCC IM Cannabis	$2.66	$2.84	$1.29 ▼ $7.12	$13.96M	2.2	51,227 shs	17,363 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
SPRC SciSparc	$4.51 -8.1%	$6.55	$4.14 ▼ $37.59	$2.41M	0.88	41,155 shs	16,075 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGC Flora Growth	0.00%	+26.75%	-3.97%	-10.34%	-33.41%
IMCC IM Cannabis	0.00%	-2.92%	-20.36%	+60.24%	-11.04%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SPRC SciSparc	0.00%	-13.10%	-43.91%	-32.02%	-33.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGC Flora Growth	3.3336 of 5 stars	3.5	5.0	0.0	0.0	3.5	0.8	0.6
IMCC IM Cannabis	0.9422 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.0
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	1.148 of 5 stars	0.0	5.0	0.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGC Flora Growth	3.00	Buy	$93.00	293.53% Upside
IMCC IM Cannabis	0.00	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
SPRC SciSparc	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPRC, PHXM, FLGC, and IMCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGC Flora Growth	$52.37M	0.26	N/A	N/A	$6.96 per share	3.40
IMCC IM Cannabis	$52.41M	0.27	N/A	N/A	$0.56 per share	4.75
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
SPRC SciSparc	$1.31M	1.85	N/A	N/A	$18.13 per share	0.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	N/A
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-59.80%	-5.15%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	-$6.28M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SPRC, PHXM, FLGC, and IMCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGC Flora Growth	0.50	0.96	0.61
IMCC IM Cannabis	0.32	0.72	0.59
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
SPRC SciSparc	N/A	5.36	5.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGC Flora Growth	36.01%
IMCC IM Cannabis	7.68%
PHXM PHAXIAM Therapeutics	0.40%
SPRC SciSparc	25.06%

Insider Ownership

Company	Insider Ownership
FLGC Flora Growth	12.56%
IMCC IM Cannabis	5.91%
PHXM PHAXIAM Therapeutics	1.94%
SPRC SciSparc	1.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGC Flora Growth	280	578,000	505,000	Not Optionable
IMCC IM Cannabis	340	5.25 million	4.94 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
SPRC SciSparc	4	535,000	527,000	Not Optionable

SPRC, PHXM, FLGC, and IMCC Headlines

Recent News About These Companies

SciSparc Announces Patent Filing and Merger Updates

August 8, 2025 | theglobeandmail.com

SciSparc and Clearmind Publish Patent for Novel Obesity Therapy

August 8, 2025 | tipranks.com

SciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and Obesity

August 7, 2025 | quiverquant.comQ

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

August 7, 2025 | globenewswire.com

SciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 31, 2025 | finanznachrichten.de

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 30, 2025 | globenewswire.com

Clearmind Medicine files international patent application under PCT

July 30, 2025 | msn.com

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

July 30, 2025 | globenewswire.com

SciSparc Ltd. Regains Nasdaq Compliance

July 22, 2025 | tipranks.com

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

July 22, 2025 | globenewswire.com

SciSparc Announces 1-for-21 Reverse Share Split - Morningstar

June 26, 2025 | morningstar.comM

SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum

June 25, 2025 | msn.com

SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share Split

June 25, 2025 | finanznachrichten.de

SciSparc Ltd. Announces One-for-Twenty One Reverse Share Split Effective July 3, 2025

June 24, 2025 | quiverquant.comQ

SciSparc Announces 1-for-21 Reverse Share Split

June 24, 2025 | globenewswire.com

SciSparc secures Japanese patent for pain relief combo

May 28, 2025 | investing.com

SciSparc Unveils Japanese Patent for Novel Pain Relief Combination

May 27, 2025 | tipranks.com

SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA

May 27, 2025 | quiverquant.comQ

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025 | globenewswire.com

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.

May 13, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC, PHXM, FLGC, and IMCC Company Descriptions

Flora Growth NASDAQ:FLGC

$23.63 +0.13 (+0.56%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$23.59 -0.04 (-0.18%)

As of 08/15/2025 06:40 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

IM Cannabis NASDAQ:IMCC

$2.66 0.00 (0.00%)

Closing price 08/15/2025 03:53 PM Eastern

Extended Trading

$2.70 +0.04 (+1.69%)

As of 08/15/2025 07:57 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/15/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

SciSparc NASDAQ:SPRC

$4.51 -0.40 (-8.15%)

Closing price 08/15/2025 03:50 PM Eastern

Extended Trading

$4.61 +0.10 (+2.11%)

As of 08/15/2025 07:33 PM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time